Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours.
BACKGROUND
Thyrotropin (TSH)-secreting pituitary adenomas (TSHomas) are rare tumours that can be invasive. It has been suggested that thyroid surgery or radioiodine treatment should not be considered in patients with such tumours as these treatments may facilitate rapid and aggressive tumour expansion.


OBJECTIVE
To study the effects of thyroid ablative treatment on tumour size and thyroid status in two patients with TSHomas in whom the size of the adenoma was clearly documented before treatment was started.


METHODS
Patients studied were: (1) a female patient with a TSHoma who declined to undergo pituitary surgery and underwent a total thyroidectomy instead and (2) a male patient who opted for radioiodine treatment for his recurrent TSHoma. Changes in tumour size on serial magnetic resonance imaging scans, and restoration of euthyroidism were studied.


RESULTS
No marked changes in tumour size or features of aggressiveness occurred in these patients over periods of 8 and 12 years. Euthyroidism was restored and maintained in both patients.


CONCLUSIONS
Ablative thyroid treatment can be a safe and successful option to treat TSHomas, but long-term and close follow-up of these patients is mandatory to ensure that the size and behaviour of the tumours do not change markedly.
Daousi
C
C
Diabetes and Endocrinology Research Group, University Hospital Aintree, Clinical Sciences Centre, 3rd Floor, Lower Lane, Liverpool L9 7AL, UK. cdaousi@liverpool.ac.uk
Foy
P M
PM
MacFarlane
I A
IA
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications*; D013961:Thyroid Gland / Q000601:surgery*; D013971:Thyrotoxicosis / Q000209:etiology* / Q000601:surgery*; D013972:Thyrotropin / Q000378:metabolism*
D013972:Thyrotropin